Tadalafil for COPD with Pulmonary Hypertension
Recruiting0 awardsPhase 2
Aurora, Colorado
This trial is testing whether tadalafil can help Veterans with COPD and high blood pressure in the lungs by reducing shortness of breath and improving overall health. The drug works by relaxing blood vessels to improve blood flow. The study will compare tadalafil to another group over several months to see if it makes a significant difference in symptoms and quality of life. Tadalafil received FDA approval in 2009 for the treatment of pulmonary arterial hypertension (PAH) and has shown to improve exercise capacity and quality of life in patients.
Radioisotope Therapy
Rhenium Re 188 P2045 for Lung Cancer
Recruiting1 awardPhase 1 & 2
Iowa City, Iowa
This trial tests a new drug called Rhenium Re 188 P2045 on lung cancer patients. It aims to find a safe dose and check if it helps reduce tumors. Patients are monitored closely for side effects and tumor response.
Cancer Vaccine
MUC1 Vaccine + PolyICLC for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial involves giving a special vaccine to patients with non-small cell lung cancer. The vaccine aims to help the immune system recognize and attack cancer cells. The goal is to see if this approach can effectively boost the body's natural defenses against lung cancer.
Tyrosine Kinase Inhibitor
Cabozantinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial will help us understand if cabozantinib can help patients with gene RET, ROS1, or NTRK fusion or increased MET or AXL activity by inhibiting these genes that lead to lung cancer cell growth.
Proton Beam Therapy
Image-Guided Radiation Therapy for Lung Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing a new way of delivering radiation dose by image-guided, intensity-modulated photon or proton beam radiation therapy to patients with stage II-IIIB non-small cell lung cancer.
Popular Filters
Trials for NSCLC Patients
Brachytherapy
CivaSheet for Lung Cancer
Recruiting1 awardPhase 2
Mission Viejo, California
This trial will test a new cancer treatment device to see if it is safe and effective. The device uses active components of standard devices in a new way, which may reduce the amount of radiation to healthy tissue while giving a therapeutic dose to diseased tissue.
Kinase Inhibitor
Tepotinib for Lung Cancer
Recruiting1 awardPhase 2
Duarte, California
This trial will study the effects of tepotinib on lung cancer growth and spread, as well as safety, side effects, and quality of life. Pharmacogenetic research may also be conducted to study how genes impact the effectiveness of the drug.
Topoisomerase II inhibitors
Chemotherapy + Radiation + Bevacizumab for Lung Cancer
Recruiting1 awardPhase 2
Mobile, Alabama
This trial is testing a combination of chemotherapy drugs, radiation therapy, and the drug bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer.
Trials for Non-Small Cell Lung Cancer Patients
Brachytherapy
CivaSheet for Lung Cancer
Recruiting1 awardPhase 2
Mission Viejo, California
This trial will test a new cancer treatment device to see if it is safe and effective. The device uses active components of standard devices in a new way, which may reduce the amount of radiation to healthy tissue while giving a therapeutic dose to diseased tissue.
Kinase Inhibitor
Tepotinib for Lung Cancer
Recruiting1 awardPhase 2
Duarte, California
This trial will study the effects of tepotinib on lung cancer growth and spread, as well as safety, side effects, and quality of life. Pharmacogenetic research may also be conducted to study how genes impact the effectiveness of the drug.
Topoisomerase II inhibitors
Chemotherapy + Radiation + Bevacizumab for Lung Cancer
Recruiting1 awardPhase 2
Mobile, Alabama
This trial is testing a combination of chemotherapy drugs, radiation therapy, and the drug bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer.
Trials for EGFR Positive Patients
Tyrosine Kinase Inhibitor
Erlotinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial compares erlotinib hydrochloride to observation in treating patients with resected stage IB-IIIA non-small cell lung cancer. Erlotinib hydrochloride may stop tumor cell growth by blocking enzymes needed for cell growth.
mTOR Kinase Inhibitor
Sapanisertib + Osimertinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
New Haven, Connecticut
This trial is testing the combination of sapanisertib and osimertinib to treat patients with lung cancer that has progressed after treatment with an EGFR tyrosine kinase inhibitor.
Trials for ALK Positive Patients
Tyrosine Kinase Inhibitor
Alectinib vs Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial compares two medications, alectinib and crizotinib, for treating a specific type of advanced lung cancer. The patients have not received any prior treatment for their cancer. Both drugs work by blocking a protein that helps the cancer cells grow. Alectinib has shown superior effectiveness and fewer side effects compared to crizotinib in treating this type of lung cancer.
Tyrosine Kinase Inhibitor
Erlotinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial compares erlotinib hydrochloride to observation in treating patients with resected stage IB-IIIA non-small cell lung cancer. Erlotinib hydrochloride may stop tumor cell growth by blocking enzymes needed for cell growth.
Kinase Inhibitor
Ceritinib + Everolimus for Lung Cancer
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing the side effects and best dosage of ceritinib and everolimus for treating patients with solid tumors that have spread from the original site. Ceritinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Phase 3 Trials
Alkylating agents
Radiation + Chemotherapy for Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing different radiation therapy regimens to see which is more effective in treating patients with limited-stage small cell lung cancer when given together with chemotherapy.
Tyrosine Kinase Inhibitor
Alectinib vs Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial compares two medications, alectinib and crizotinib, for treating a specific type of advanced lung cancer. The patients have not received any prior treatment for their cancer. Both drugs work by blocking a protein that helps the cancer cells grow. Alectinib has shown superior effectiveness and fewer side effects compared to crizotinib in treating this type of lung cancer.
Proton Beam Therapy
Photon vs Proton Radiation for Non-Small Cell Lung Cancer
Recruiting3 awardsPhase 3
Jacksonville, Florida
This trial is comparing two types of radiation therapy to see which is more effective in treating patients with stage II-IIIB non-small cell lung cancer- proton chemoradiotherapy versus photon chemoradiotherapy.
Tyrosine Kinase Inhibitor
Erlotinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial compares erlotinib hydrochloride to observation in treating patients with resected stage IB-IIIA non-small cell lung cancer. Erlotinib hydrochloride may stop tumor cell growth by blocking enzymes needed for cell growth.
Trials With No Placebo
Procedure
Cryobiopsy vs Forceps Biopsy for Lung Disease
Recruiting1 award2 criteria
Baltimore, Maryland
This trial compares a new method to a standard one for lung biopsies. It targets patients needing lung tissue samples, aiming to improve sample quality and reduce complications. The new method works by freezing and removing tissue, providing larger and higher-quality samples with a good safety and cost-benefit profile.
Brachytherapy
CivaSheet for Lung Cancer
Recruiting1 awardPhase 2
Mission Viejo, California
This trial will test a new cancer treatment device to see if it is safe and effective. The device uses active components of standard devices in a new way, which may reduce the amount of radiation to healthy tissue while giving a therapeutic dose to diseased tissue.
Kinase Inhibitor
Tepotinib for Lung Cancer
Recruiting1 awardPhase 2
Duarte, California
This trial will study the effects of tepotinib on lung cancer growth and spread, as well as safety, side effects, and quality of life. Pharmacogenetic research may also be conducted to study how genes impact the effectiveness of the drug.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.